InProTher announces EUR 6MSeed financing with the participation of the European Innovation Council Fund to develop first-in-class cancer immunotherapy
• Danish start-up developing immunotherapies designed to fight the tumors from within
• Financing supports GMP and tox studies and will advance InProTher’s first-in-class cancer immunotherapy into First-in-Human clinical trials
• Strengthens team with appointment of industry heavyweights Dr. Sven Rohman as Chairman and Dr. Hamina Patel as CMO
Copenhagen, Denmark, 24 May 2023: InProTher, an early-stage biotechnologycompany developing effective immunotherapies targeting the Human Endogenous Retroviruses (HERVs), today announces that it has raised EUR 6M of Seed funding from private investors with the participation of the European Innovation Council (EIC) Fund. The financing will enable InProTher to advance its lead drug candidate, IPT001, a first-in-class immunotherapy against solid tumors, into clinical development.
